Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.
Also called NCT01805830
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 189 participants
- Sponsor
- Registry
-
NCT01805830
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01805830. Randomized; double masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy
- Acronym
- T2DM
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- MP513
- Intervention (Drug)
- Placebo
- Lead sponsor
- Handok Inc.
Record details
- Record id
cardio:ct-nct01805830- Content hash
a87fa478063c6a2fa4b4ea95b5820e478cc251d4767735a4fd0cf5127534232c